PharmAthene has appointed Linda Chang as senior vice president (SVP) and chief financial officer (CFO). Chang is responsible for accounting, finance, IT and investor relations functions.
Prior to joining PharmAthene, Chang spent 11 years at Human Genome Sciences, most recently as senior director of finance. She was a key member of the team that raised over US$1.8bn in equity, issued and restructured over US$600m in convertible debt, and transacted over US$950m in real estate financing. Chang also managed as much as US$1.6 bn in investment portfolios, negotiated letters of credit (L/Cs), and participated in business development efforts, including the purchase of Principia Corporation.
Prior to Human Genome Sciences, Chang was an associate at Booz Allen & Hamilton from 1997 to 2000. Earlier in her career, Chang worked at Grant Thornton and Otsuka America Pharmaceuticals.
Chang is a certified public accountant (CPA). She earned an MBA as well as a Master of Accountancy degree from the University of Georgia and a BS from the University of California, Riverside.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more